PL3197456T3 - Leczenie nowotworów - Google Patents

Leczenie nowotworów

Info

Publication number
PL3197456T3
PL3197456T3 PL15726258T PL15726258T PL3197456T3 PL 3197456 T3 PL3197456 T3 PL 3197456T3 PL 15726258 T PL15726258 T PL 15726258T PL 15726258 T PL15726258 T PL 15726258T PL 3197456 T3 PL3197456 T3 PL 3197456T3
Authority
PL
Poland
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
PL15726258T
Other languages
English (en)
Inventor
Hugh GRIFFITH
Chris Mcguigan
Chris Pepper
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3197456(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NuCana plc filed Critical NuCana plc
Publication of PL3197456T3 publication Critical patent/PL3197456T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL15726258T 2015-05-14 2015-05-14 Leczenie nowotworów PL3197456T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB2015/051438 WO2016181093A1 (en) 2015-05-14 2015-05-14 Cancer treatments
EP15726258.5A EP3197456B2 (en) 2015-05-14 2015-05-14 Cancer treatments

Publications (1)

Publication Number Publication Date
PL3197456T3 true PL3197456T3 (pl) 2018-09-28

Family

ID=53276184

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15726258T PL3197456T3 (pl) 2015-05-14 2015-05-14 Leczenie nowotworów

Country Status (26)

Country Link
US (3) US20180289733A1 (pl)
EP (2) EP3415149A1 (pl)
JP (1) JP6761852B2 (pl)
KR (1) KR20180021697A (pl)
CN (2) CN107835687A (pl)
AU (2) AU2015394135B2 (pl)
BR (1) BR112017024461B1 (pl)
CA (1) CA2985540C (pl)
CY (1) CY1120516T1 (pl)
DK (1) DK3197456T3 (pl)
EA (1) EA201792509A1 (pl)
ES (1) ES2668377T3 (pl)
HR (1) HRP20180762T1 (pl)
HU (1) HUE038541T2 (pl)
IL (1) IL255591B (pl)
LT (1) LT3197456T (pl)
MX (2) MX374946B (pl)
MY (1) MY192081A (pl)
PH (1) PH12017502086B1 (pl)
PL (1) PL3197456T3 (pl)
PT (1) PT3197456T (pl)
RS (1) RS57371B1 (pl)
SI (1) SI3197456T1 (pl)
SM (1) SMT201800303T1 (pl)
TR (1) TR201806642T4 (pl)
WO (1) WO2016181093A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ES3039965T3 (en) 2011-03-01 2025-10-28 NuCana plc Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
ES2725491T3 (es) 2012-11-16 2019-09-24 Univ College Cardiff Consultants Ltd Mezcla de RP/SP gemcitabina-[fenil-(benciloxi-L-alaninil)]-fosfato
RS60968B1 (sr) 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
PT3119794T (pt) 2014-06-25 2018-01-15 Nucana Biomed Ltd Formulação que compreende um pró-fármaco de gemcitabina
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
SG10202009020VA (en) 2014-11-28 2020-10-29 NuCana plc New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
CN108271375A (zh) 2015-09-25 2018-07-10 豪夫迈·罗氏有限公司 包含分选酶缀合环的重组免疫球蛋白重链及其缀合物
CA2994502C (en) 2015-10-05 2023-08-01 NuCana plc Combination therapy comprising nuc-1031 and carboplatin for cancer treatment
KR20180101370A (ko) 2015-12-11 2018-09-12 뉴카나 피엘씨 인산염 유도체 및 젬시타빈 전구약물 nuc-1031의 부분입체 이성질체 선별적 합성
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
CA3008769A1 (en) * 2015-12-23 2017-06-29 NuCana plc Combination therapy comprising nuc-1031 and cisplatin
EP3393478B1 (en) * 2015-12-23 2020-03-04 NuCana plc Combination therapy
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
WO2020077353A2 (en) * 2018-10-12 2020-04-16 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for reducing cancer stem cells
CN117398401B (zh) * 2021-01-31 2025-10-10 兰州大学 齐多夫定在制备预防和/或治疗酒精性胃溃疡药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EP3067054B1 (en) * 2007-09-10 2020-12-30 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
CN102144163A (zh) * 2008-04-10 2011-08-03 麻省理工学院 关于鉴定和使用靶向癌症干细胞的试剂的方法

Also Published As

Publication number Publication date
WO2016181093A1 (en) 2016-11-17
JP2018515618A (ja) 2018-06-14
EP3197456A1 (en) 2017-08-02
IL255591B (en) 2021-10-31
IL255591A (en) 2018-01-31
JP6761852B2 (ja) 2020-09-30
EP3197456B1 (en) 2018-04-04
CA2985540C (en) 2021-08-24
CN107835687A (zh) 2018-03-23
EA201792509A1 (ru) 2018-05-31
KR20180021697A (ko) 2018-03-05
AU2021277614A1 (en) 2021-12-23
BR112017024461B1 (pt) 2023-04-04
PT3197456T (pt) 2018-05-22
DK3197456T3 (en) 2018-06-06
PH12017502086A1 (en) 2018-04-30
MX374946B (es) 2025-03-06
US20210100825A1 (en) 2021-04-08
SMT201800303T1 (it) 2018-07-17
US20180289733A1 (en) 2018-10-11
EP3197456B2 (en) 2023-10-11
CA2985540A1 (en) 2016-11-17
PH12017502086B1 (en) 2022-12-09
US20230226092A1 (en) 2023-07-20
ES2668377T3 (es) 2018-05-17
MX2020009154A (es) 2022-03-08
MY192081A (en) 2022-07-26
AU2015394135B2 (en) 2021-09-16
TR201806642T4 (tr) 2018-06-21
HRP20180762T1 (hr) 2018-08-24
RS57371B1 (sr) 2018-08-31
SI3197456T1 (en) 2018-08-31
EP3415149A1 (en) 2018-12-19
AU2015394135A1 (en) 2017-12-14
MX390506B (es) 2025-03-20
MX2017014544A (es) 2018-09-26
HUE038541T2 (hu) 2018-10-29
LT3197456T (lt) 2018-07-10
BR112017024461A2 (pt) 2018-07-24
CY1120516T1 (el) 2019-07-10
CN115837028A (zh) 2023-03-24

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
IL255261A0 (en) Methods for treating cancer
IL269026A (en) Methods of treating tumor
PL3283527T3 (pl) Leczenie skojarzone nowotworów
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
PL3197456T3 (pl) Leczenie nowotworów
DK3240801T3 (da) Kombinationstumorimmunterapi
EP3291824A4 (en) ANTIMICROBIAL THERAPY
HUE059694T2 (hu) Készítmény rák kezelésére
IL284875A (en) Lasofoxifene treatment of breast cancer
KR20180084772A (ko) 암 치료를 위한 조합 치료법
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
PL3458052T3 (pl) Leczenie skojarzone nowotworu
IL265697B1 (en) Treatment of prostate cancer
EP3546020A4 (en) CANCER TREATMENT APPARATUS
DK3576740T3 (da) Cancerbehandling
PL3134119T3 (pl) Leczenie nowotworu
EP3413927A4 (en) CANCER THERAPY
EP3593139C0 (en) CANCER BIOMARKERS
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
DK3393478T3 (da) Kombinationsterapi
EP3362091A4 (en) COMBINATION THERAPY
DK3302478T3 (da) Pac-1 kombinations behandling
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
IL264277A (en) Crebbp related cancer therapy